

## Disclosures

### Personal Commercial (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
BridgeBio	Speaker's Bureau	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (10)

Trial Name	Trial Sponsor	Trial Funding Source
TRITON-CM: A Study to Evaluate Nucleosiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy	Alnylam	
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study	Ancora Heart	
EIDOS AG10-304: Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants	Eidos Therapeutics, a BridgeBio company	
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM)	Eidos Therapeutics, a BridgeBio company	
Evolut™ EXPAND TAVR II Pivotal Trial	MEDTRONIC	
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)	Novo Nordisk A/S	
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)	Novo Nordisk Inc.	
TRITON-CM: A Study to Evaluate Nucleosiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy	Novo Nordisk Inc.	
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis	Novo Nordisk Inc.	
Global Prevalence of ATTR-CM in Participants With HFpEF	Pfizer	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 6/24/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 6/24/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 6/24/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 6/24/2026

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.